Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03602040
Other study ID # 249303
Secondary ID ICA-CDRF-2015-01
Status Suspended
Phase N/A
First received
Last updated
Start date June 2022
Est. completion date June 2024

Study information

Verified date February 2021
Source King's College London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Inherited heart conditions (IHCs) can cause young sudden deaths due to a genetic trait that leads to a thickened heart muscle or abnormal heart rhythms. Relatives of an affected person have a 50% chance of inheriting IHCs and this is determined either through a blood test (predictive genetic test) and/or physical tests such as a heart tracing (electrocardiogram), scan (echocardiogram) and exercise test. When patients find out they are affected or are carriers for an IHC, they have numerous questions about medical management, prognosis, lifestyle; as well as experiencing stress and anxiety because of the impact on their health and risk to their family. Based on published studies and interviews, a psychoeducational intervention underpinned by Self-determination Theory was developed to support these patients An uncontrolled study to determine the feasibility of the intervention and outcome measures will be undertaken. Patients with a new IHC diagnosis or a carrier result aged 16 years and older will be recruited from outpatient clinics in London and will be receive the intervention consisting of a disease-specific information leaflet, a personalised lifestyle consideration guide and participation in a 1-hour group session facilitated by a cardiac genetic nurse. Outcome measures to look at degree of self-determination, autonomy support and competence; and heart-related anxiety will be collected at baseline and at 3 months post intervention. Clinical and socio-demographic data will be obtained from medical notes. The feasibility and acceptability of the intervention will be measured by assessment of the study procedures such as recruitment, retention and any adverse events. It is expected that there will be up to 4 consecutive group sessions and feedback from each session will be used to co-design and refine the intervention model for a definitive clinical trial.


Recruitment information / eligibility

Status Suspended
Enrollment 24
Est. completion date June 2024
Est. primary completion date June 2023
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: 1. Patients who are aged 16 and older. 2. Patients who have undergone cardiac screening and/or predictive genetic testing for inherited cardiac conditions and are within 6 months of receiving a new diagnosis of an inherited cardiac condition (ICC) and/or have been found to be carriers of a genetic alteration that can cause an ICC. Exclusion Criteria: 1. Patients who were initially referred to the clinic for reasons other than cardiac screening and/or predictive genetic testing for ICCs. 2. Patients who have undergone cardiac screening and/or predictive genetic testing for ICCs and more than 6 months have passed since receiving a new diagnosis of an ICC and/or a carrier result for a genetic alteration that can cause an ICC. 3. Patients who have undergone cardiac screening and/or predictive genetic testing for ICCs and have received a negative result. 4. Patients below 16 years of age. 5. Patients with insufficient command of written and spoken English to comprehend study documents and participate in the study procedures and discussion. 6. Patients who are already participating in a study involving a psychoeducational intervention, novel cardiac medication or device.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
PISICC
PISICC consists of: Standard disease-specific information leaflet Personalised lifestyle consideration form 1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c).

Locations

Country Name City State
United Kingdom King's College Hospital London

Sponsors (4)

Lead Sponsor Collaborator
King's College London Guy's and St Thomas' NHS Foundation Trust, King's College Hospital NHS Trust, National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Process evaluation (Qualitative interviews) Nested qualitative component of the study consisting of semi-structured interviews with a subset of patients who participated in the study. The topic guide will gather insights on the patient experience of the intervention and trial procedures. All interviews will be digitally recorded, transcribed and thematic analysis will be facilitated by NVivo software. 3 months
Primary Engagement of clinical staff with identification of patients Number of participants identified for recruitment 3 months
Primary Engagement of participants with recruitment procedures Number of participants consented, number of participants declined and withdrawn 3 months
Primary Completion of data collection Rates of data collection at baseline and follow-up, and reasons for missing data 3 months
Primary Engagement with psychoeducational intervention Rates of intervention uptake and reasons for dropout 3 months
Secondary Perceived Competence Scale A short 4-item questionnaire assessing feelings of competence about a specific domain. In this case, this is for the management of the diagnosis or carrier status. The score ranges from 28 (high perceived competence) to 4 (low perceived competence) Metric for summarising data: t-test Measured at baseline and 3 months post intervention
Secondary Perceived Choice and Awareness of Self Scale A short, 10-item scale, with two 5-item subscales pertaining to perception of choice in one's actions and awareness of oneself. The total score ranges from 50 (high perceived choice and awareness of self) to 10 (low perceived choice and awareness of self). For the perceived choice subscale, the score ranges from 25 (high perceived choice) to 5 (low perceived choice). For the perceived awareness of self subscale, the score ranges from 5 (high perceived awareness of self) to 1 (low perceived awareness of self) Metric for summarising data: t-test Measured at baseline and 3 months post intervention
Secondary Health Care Climate Questionnaire A 15-item questionnaire to assess the patients' perception of the degree to which their health care team is supporting their autonomy. The average score ranges from 7 (high perceived autonomy support from clinicians) to 1 (low perceived autonomy support from clinicians).
Metric for summarising data: t-test
Measured at baseline and 3 months post intervention
Secondary Heart-related Anxiety (Questionnaire) Cardiac Anxiety Questionnaire-an 18-tem self-reported questionnaire designed to measure heart-focused anxiety. The total score ranges from 72 (high heart-related anxiety) to 0 (low heart-related anxiety) Metric for summarising data: t-test Measured at baseline and 3 months post intervention
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05428787 - Resynchronization in Patients With HF in AF Trial Undergoing Pace & AVNA Strategy With LBBAP Compared With BiV Pacing N/A
Not yet recruiting NCT05567445 - Outcome of Cardiomyopathic Adults Admission in ICU.
Completed NCT02555527 - Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment N/A
Completed NCT00371891 - Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Phase 4
Recruiting NCT05552521 - Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants
Recruiting NCT04166331 - Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion Phase 3
Terminated NCT06331507 - Refinement and Assessment of New MRI Technologies for Cardiovascular Exams Using the Phillips CMR Patch N/A
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Recruiting NCT04695119 - Sepsis in the ICU-II
Completed NCT03228966 - Ped HIV - Echo Study: Kenya
Not yet recruiting NCT06348732 - Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings
Recruiting NCT05556369 - Genetic Characterization of Cardiomyopathies (POLICARDIOMIO2021)
Recruiting NCT04520646 - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy N/A
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04323852 - Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery? Phase 4
Completed NCT03527381 - Nitric Oxide in Cardiopulmonary Bypass for Renal Protection in Cardiac Surgery Phase 1/Phase 2
Withdrawn NCT02462213 - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging N/A
Active, not recruiting NCT00418041 - Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study) N/A
Not yet recruiting NCT06091475 - Therapy to Maintain Remission in Dilated Cardiomyopathy N/A
Recruiting NCT03317964 - Genetic Basis of Pacing-induced Cardiomyopathy